Sex-Specific Disparities in Outcomes of Transcatheter Edge-to-Edge Repair for Mitral Regurgitation: A Multicenter "Real-World" Analysis.

MitraClip PASCAL arrhythmia atrial fibrillation gender outcome percutaneous mitral valve repair

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
22 Nov 2023
Historique:
received: 17 10 2023
revised: 09 11 2023
accepted: 18 11 2023
medline: 9 12 2023
pubmed: 9 12 2023
entrez: 9 12 2023
Statut: epublish

Résumé

mitral regurgitation (mr) is the most common valvular heart disease (vhd) in the elderly and tends to be more prevalent in women. while relevant sex differences in outcomes are evident in surgically treated collectives, there are very limited and conflicting sex-specific data for the growing cohort of patients undergoing transcatheter edge-to-edge repair (teer). to investigate whether sex impacts procedural safety and efficacy, and in-hospital- and long-term outcomes, after teer for mr. in a multicenter observational cohort study, patients who underwent teer were stratified by sex and relevant outcome measures, and analyzed using multivariable cox regression and propensity score matching (psm). a total of 821 patients were analyzed, of whom 37.4% (307/821) were female. compared to male patients, females were significantly older (77 ± 8.5 vs. 80.4 ± 6.7 years, female patients are older and less comorbid than males undergoing TEER. The TEER procedure is equally safe and effective in both sexes. While in-hospital mortality did not differ, female patients experienced a significantly better adjusted long-term survival compared to male patients. Concomitant AF offsets the prognostic advantage of females over males and, in contrast to males, significantly impairs long-term survival in women undergoing TEER. Further research is warranted to elucidate underlying causes for the observed sex disparities and to develop sex-tailored treatment recommendations.

Sections du résumé

BACKGROUND BACKGROUND
mitral regurgitation (mr) is the most common valvular heart disease (vhd) in the elderly and tends to be more prevalent in women. while relevant sex differences in outcomes are evident in surgically treated collectives, there are very limited and conflicting sex-specific data for the growing cohort of patients undergoing transcatheter edge-to-edge repair (teer).
OBJECTIVE OBJECTIVE
to investigate whether sex impacts procedural safety and efficacy, and in-hospital- and long-term outcomes, after teer for mr.
METHODS METHODS
in a multicenter observational cohort study, patients who underwent teer were stratified by sex and relevant outcome measures, and analyzed using multivariable cox regression and propensity score matching (psm).
RESULTS RESULTS
a total of 821 patients were analyzed, of whom 37.4% (307/821) were female. compared to male patients, females were significantly older (77 ± 8.5 vs. 80.4 ± 6.7 years,
CONCLUSIONS CONCLUSIONS
female patients are older and less comorbid than males undergoing TEER. The TEER procedure is equally safe and effective in both sexes. While in-hospital mortality did not differ, female patients experienced a significantly better adjusted long-term survival compared to male patients. Concomitant AF offsets the prognostic advantage of females over males and, in contrast to males, significantly impairs long-term survival in women undergoing TEER. Further research is warranted to elucidate underlying causes for the observed sex disparities and to develop sex-tailored treatment recommendations.

Identifiants

pubmed: 38068282
pii: jcm12237231
doi: 10.3390/jcm12237231
pmc: PMC10706895
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Biomolecules. 2018 Nov 19;8(4):
pubmed: 30463247
EuroIntervention. 2016 Jun 12;12(2):e257-64
pubmed: 27290685
N Engl J Med. 2018 Dec 13;379(24):2307-2318
pubmed: 30280640
JACC Cardiovasc Interv. 2021 Apr 26;14(8):819-827
pubmed: 33812815
Lancet. 2021 Jun 19;397(10292):2385-2438
pubmed: 34010613
Am J Cardiol. 2020 May 1;125(9):1391-1397
pubmed: 32151434
Open Heart. 2020 Aug;7(2):
pubmed: 32788294
N Engl J Med. 2011 Apr 14;364(15):1395-406
pubmed: 21463154
Heart Fail Rev. 2021 May;26(3):531-543
pubmed: 33169339
BMJ. 2016 Jan 19;532:h7013
pubmed: 26786546
Catheter Cardiovasc Interv. 2020 Mar 1;95(4):819-829
pubmed: 31233278
Eur J Heart Fail. 2013 Aug;15(8):919-27
pubmed: 23512096
Am J Cardiol. 2020 Oct 1;132:179-181
pubmed: 32768141
N Engl J Med. 2018 Dec 13;379(24):2297-2306
pubmed: 30145927
Nat Rev Cardiol. 2021 Dec;18(12):853-864
pubmed: 34172950
JACC Heart Fail. 2021 Sep;9(9):674-683
pubmed: 34391744
Eur Heart J. 2016 Dec 14;37(47):3515-3522
pubmed: 27354049
Am J Cardiol. 2023 Oct 15;205:12-19
pubmed: 37579655
Medicina (Kaunas). 2023 May 24;59(6):
pubmed: 37374220
J Interv Cardiol. 2020 Aug 28;2020:6542028
pubmed: 32934608
JACC Cardiovasc Interv. 2019 Mar 25;12(6):569-578
pubmed: 30898255
Heart. 2017 Nov;103(21):1696-1703
pubmed: 28432156
J Am Heart Assoc. 2020 Aug 4;9(15):e016086
pubmed: 32696692
Europace. 2007 Sep;9 Suppl 4:iv1-3
pubmed: 17766319
Circ Cardiovasc Interv. 2021 Nov;14(11):e009374
pubmed: 34784236
Eur J Heart Fail. 2019 Feb;21(2):196-204
pubmed: 30549159
J Clin Med. 2021 Oct 28;10(21):
pubmed: 34768567
Scand J Surg. 2022 Dec;111(4):99-109
pubmed: 36112913
Cardiovasc Revasc Med. 2018 Mar;19(2):182-185
pubmed: 28784307
ESC Heart Fail. 2021 Oct;8(5):3539-3546
pubmed: 34363328
Biomed Res Int. 2016;2016:3934842
pubmed: 27042662
Ann Thorac Surg. 2013 Oct;96(4):1367-1373
pubmed: 23915585
Thromb Res. 2013 Aug;132(2):185-9
pubmed: 23932014
Eur Heart J. 2015 Aug 1;36(29):1878-91
pubmed: 26170468
Catheter Cardiovasc Interv. 2015 Apr;85(5):889-97
pubmed: 25367550
Circ Res. 2022 Feb 18;130(4):455-473
pubmed: 35175844
Catheter Cardiovasc Interv. 2022 May;99(6):1819-1828
pubmed: 35094482
J Interv Cardiol. 2022 Feb 21;2022:5488654
pubmed: 35281587
Lancet. 2006 Sep 16;368(9540):1005-11
pubmed: 16980116
Am J Cardiol. 2017 Dec 1;120(11):2035-2040
pubmed: 29033048
Eur J Heart Fail. 2020 Aug;22(8):1342-1356
pubmed: 32483830
J Interv Cardiol. 2018 Dec;31(6):925-931
pubmed: 30456770

Auteurs

Felix Ausbuettel (F)

Department of Cardiology, University Hospital Marburg, Philipps University Marburg, Baldingerstraße, 35043 Marburg, Germany.

Sebastian Barth (S)

Department of Cardiology, Cardiovascular Center Bad Neustadt/Saale, Von-Guttenberg-Straße 11, 97616 Bad Neustadt/Saale, Germany.

Georgios Chatzis (G)

Department of Cardiology, University Hospital Marburg, Philipps University Marburg, Baldingerstraße, 35043 Marburg, Germany.

Kiarash Sassani (K)

Department of Cardiology, University Hospital Marburg, Philipps University Marburg, Baldingerstraße, 35043 Marburg, Germany.

Dieter Fischer (D)

Department of Cardiology, Cardiovascular Center Rotenburg/Fulda, Heinz-Meise-Straße 100, 36199 Rotenburg/Fulda, Germany.

Sebastian Weyand (S)

Department of Cardiology, Ostalb Clinic Aalen, Im Kaelblesrein 1, 73430 Aalen, Germany.

Julian Mueller (J)

Department of Cardiology, University Hospital Marburg, Philipps University Marburg, Baldingerstraße, 35043 Marburg, Germany.
Department of Cardiology, Cardiovascular Center Bad Neustadt/Saale, Von-Guttenberg-Straße 11, 97616 Bad Neustadt/Saale, Germany.

Harald Schuett (H)

Department of Cardiology, University Hospital Marburg, Philipps University Marburg, Baldingerstraße, 35043 Marburg, Germany.

Bernhard Schieffer (B)

Department of Cardiology, University Hospital Marburg, Philipps University Marburg, Baldingerstraße, 35043 Marburg, Germany.

Ulrich Luesebrink (U)

Department of Cardiology, University Hospital Marburg, Philipps University Marburg, Baldingerstraße, 35043 Marburg, Germany.

Christian Waechter (C)

Department of Cardiology, University Hospital Marburg, Philipps University Marburg, Baldingerstraße, 35043 Marburg, Germany.

Classifications MeSH